1404 related articles for article (PubMed ID: 26016701)
21. Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Sharma S; Sharma T; Dhingra R; Tomar P; Singh S; Malhotra M; Bhardwaj TR
Mini Rev Med Chem; 2013 Oct; 13(11):1685-90. PubMed ID: 24001336
[TBL] [Abstract][Full Text] [Related]
22. Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents.
Tse Y; Armstrong D; Andrews CN; Bitton A; Bressler B; Marshall J; Liu LW
Can J Gastroenterol Hepatol; 2017; 2017():8612189. PubMed ID: 28271055
[No Abstract] [Full Text] [Related]
23. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
Miner PB
Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
[TBL] [Abstract][Full Text] [Related]
24. Update on Pharmacotherapy for Irritable Bowel Syndrome.
Munjal A; Dedania B; Cash B
Curr Gastroenterol Rep; 2019 Apr; 21(6):25. PubMed ID: 31025114
[TBL] [Abstract][Full Text] [Related]
25. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype.
Solem CT; Patel H; Mehta S; Mody R; Macahilig C; Gao X
Curr Med Res Opin; 2016 May; 32(5):899-905. PubMed ID: 26836030
[TBL] [Abstract][Full Text] [Related]
26. Tenapanor for constipation-predominant irritable bowel syndrome.
Siddiqui S; Cash BD
Drugs Today (Barc); 2020 Mar; 56(3):203-210. PubMed ID: 32282867
[TBL] [Abstract][Full Text] [Related]
27. New pharmacological treatment options for chronic constipation.
Corsetti M; Tack J
Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106
[TBL] [Abstract][Full Text] [Related]
28. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation.
Cash BD; Sharma A; Walker A; Laitman AP; Chang L
Neurogastroenterol Motil; 2023 Sep; 35(9):e14632. PubMed ID: 37332239
[TBL] [Abstract][Full Text] [Related]
29. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
Jadallah KA; Kullab SM; Sanders DS
World J Gastroenterol; 2014 Jul; 20(27):8898-909. PubMed ID: 25083062
[TBL] [Abstract][Full Text] [Related]
30. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
[TBL] [Abstract][Full Text] [Related]
31. Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
McCormack PL
Drugs; 2014 Jan; 74(1):53-60. PubMed ID: 24293117
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older.
Menees SB; Franklin H; Chey WD
Clin Ther; 2020 Jul; 42(7):1406-1414.e4. PubMed ID: 32660770
[TBL] [Abstract][Full Text] [Related]
33. Review article: current and future treatment approaches for IBS with constipation.
Liu JJ; Brenner DM
Aliment Pharmacol Ther; 2021 Dec; 54 Suppl 1():S53-S62. PubMed ID: 34927760
[TBL] [Abstract][Full Text] [Related]
34. Lubiprostone: RU 0211, SPI 0211.
Drugs R D; 2005; 6(4):245-8. PubMed ID: 15991886
[TBL] [Abstract][Full Text] [Related]
35. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
[TBL] [Abstract][Full Text] [Related]
36. Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation.
Liu JJ; Brenner DM
Gastroenterol Clin North Am; 2021 Sep; 50(3):639-653. PubMed ID: 34304792
[TBL] [Abstract][Full Text] [Related]
37. Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.
Brenner DM; Harris LA; Chang CH; Waldman SA; Poppers DM; Kassebaum-Ladewski A; Sayuk GS
Am J Gastroenterol; 2022 Apr; 117(4S):S21-S26. PubMed ID: 35354772
[TBL] [Abstract][Full Text] [Related]
38. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
39. Systematic review with meta-analysis: lubiprostone efficacy on the treatment of patients with constipation.
Passos MDCF; Takemoto MLS; Corradino GC; Guedes LS
Arq Gastroenterol; 2020; 57(4):498-506. PubMed ID: 33331483
[TBL] [Abstract][Full Text] [Related]
40. Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.
Góngora-Benítez M; Tulla-Puche J; Albericio F
Future Med Chem; 2013 Mar; 5(3):291-300. PubMed ID: 23464519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
